{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:51:57Z","timestamp":1790880717754,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100018046","name":"Nippon Kayaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s40264-023-01340-1","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T19:01:51Z","timestamp":1694545311000},"page":"991-1005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies"],"prefix":"10.1007","volume":"46","author":[{"given":"Tsutomu","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2350-6189","authenticated-orcid":false,"given":"Kiyohiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumika","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Hibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"issue":"10","key":"1340_CR1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","volume":"72","author":"W Park","year":"2013","unstructured":"Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203091.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1340_CR2","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","volume":"25","author":"T Takeuchi","year":"2015","unstructured":"Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817\u201324. https:\/\/doi.org\/10.3109\/14397595.2015.1022297.","journal-title":"Mod Rheumatol"},{"issue":"5","key":"1340_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Wiland P, Zawadzki M, Ivanova D, Kasay AB, El-Khouri EC, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology (Oxford). 2021;60(5):2277\u201387. https:\/\/doi.org\/10.1093\/rheumatology\/keaa580.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"1340_CR4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40261-022-01162-6","volume":"42","author":"R Alten","year":"2022","unstructured":"Alten R, An Y, Kim DH, Yoon S, Peyrin-Biroulet L. Re-routing infliximab therapy: subcutaneous infliximab opens a path towards greater convenience and clinical benefit. Clin Drug Investig. 2022;42(6):477\u201389. https:\/\/doi.org\/10.1007\/s40261-022-01162-6.\u00a0","journal-title":"Clin Drug Investig"},{"issue":"10","key":"1340_CR5","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","volume":"72","author":"DH Yoo","year":"2013","unstructured":"Yoo DH, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2012-203090.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1340_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","volume":"27","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27(2):237\u201345. https:\/\/doi.org\/10.1080\/14397595.2016.1206244.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"1340_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.5217\/ir.2019.00030","volume":"17","author":"T Nakagawa","year":"2019","unstructured":"Nakagawa T, Kobayashi T, Nishikawa K, Yamada F, Asai S, Sameshima Y, et al. Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice. Intest Res. 2019;17(4):504\u201315. https:\/\/doi.org\/10.5217\/ir.2019.00030.","journal-title":"Intest Res"},{"issue":"8","key":"1340_CR8","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/jgh.15399","volume":"36","author":"S Sagami","year":"2021","unstructured":"Sagami S, Nishikawa K, Yamada F, Suzuki Y, Watanabe M, Hibi T. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. J Gastroenterol Hepatol. 2021;36(8):2091\u2013100. https:\/\/doi.org\/10.1111\/jgh.15399.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1340_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/mr\/roab068","volume":"32","author":"T Takeuchi","year":"2022","unstructured":"Takeuchi T, Nishikawa K, Yamada F, Ohshima S, Inoue M, Yoshioka Y, et al. Real-world safety and efficacy of CT-P13, an infliximab biosimilar, in Japanese rheumatoid arthritis patients na\u00efve to or switched from biologics. Mod Rheumatol. 2022;32(4):718\u201327. https:\/\/doi.org\/10.1093\/mr\/roab068.","journal-title":"Mod Rheumatol"},{"issue":"10","key":"1340_CR10","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1111\/1346-8138.16508","volume":"49","author":"A Morita","year":"2022","unstructured":"Morita A, Nishikawa K, Yamada F, Yamanaka K, Nakajima H, Ohtsuki M. Safety, efficacy, and drug survival of the infliximab biosimilar CT-P13 in post-marketing surveillance of Japanese patients with psoriasis. J Dermatol. 2022;49(10):957\u201369. https:\/\/doi.org\/10.1111\/1346-8138.16508.","journal-title":"J Dermatol"},{"issue":"6","key":"1340_CR11","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"G Wells","year":"2009","unstructured":"Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Ann Rheum Dis. 2009;68(6):954\u201360. https:\/\/doi.org\/10.1136\/ard.2007.084459.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1340_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0016-5085(76)80163-1","volume":"70","author":"WR Best","year":"1976","unstructured":"Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn\u2019s disease activity index. National Cooperative Crohn\u2019s Disease Study. Gastroenterology. 1976;70(3):439\u201344.","journal-title":"Gastroenterology"},{"issue":"23","key":"1340_CR13","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Engl J Med"},{"issue":"5","key":"1340_CR14","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsleyet R, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366. https:\/\/doi.org\/10.1111\/bjd.18333.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1340_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2005.06502.x","volume":"152","author":"AY Finlay","year":"2005","unstructured":"Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(2):861\u20137. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.06502.x.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1340_CR16","doi-asserted-by":"publisher","first-page":"15051","DOI":"10.1038\/s41598-021-94504-x","volume":"11","author":"C S\u00e1nchez-Piedra","year":"2021","unstructured":"S\u00e1nchez-Piedra C, Sueiro-Delgado D, Garc\u00eda-Gonz\u00e1lez J, Ros-Vilamajo I, Prior-Espa\u00f1ol A, Moreno-Ramos MJ, et al. Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years. Sci Rep. 2021;11(1):15051. https:\/\/doi.org\/10.1038\/s41598-021-94504-x.","journal-title":"Sci Rep"},{"issue":"7","key":"1340_CR17","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/jdv.16205","volume":"34","author":"G Shalom","year":"2020","unstructured":"Shalom G, Cohen AD, Feldhamer I, Comaneshter D, Freud T, Pavlovsky L. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J Eur Acad Dermatol Venereol. 2020;34(7):1524\u20138. https:\/\/doi.org\/10.1111\/jdv.16205.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1340_CR18","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631\u20137. https:\/\/doi.org\/10.1136\/ard.2009.123919.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1340_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryantet RV, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324\u201338. https:\/\/doi.org\/10.1038\/ajg.2015.233.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1340_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11(1):235\u201352. https:\/\/doi.org\/10.1007\/s13555-020-00475-8.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"7","key":"1340_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","volume":"41","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, Mar\u00edn AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613\u201323. https:\/\/doi.org\/10.1111\/apt.13083.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1340_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard.2007.072967","volume":"67","author":"T Takeuchi","year":"2008","unstructured":"Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(2):189\u201394. https:\/\/doi.org\/10.1136\/ard.2007.072967.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1340_CR23","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/1346-8138.13214","volume":"43","author":"H Torii","year":"2016","unstructured":"Torii H, Terui T, Matsukawa M, Takesaki K, Ohtsuki M, Nakagawa H. Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: results from the prospective post-marketing surveillance. J Dermatol. 2016;43(7):767\u201378. https:\/\/doi.org\/10.1111\/1346-8138.13214.","journal-title":"J Dermatol"},{"issue":"4","key":"1340_CR24","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40259-020-00421-2","volume":"34","author":"SJ Lee","year":"2020","unstructured":"Lee SJ, Baek K, Lee S, Lee YJ, Park JE, Lee SG. Post-marketing pooled safety analysis for CT-P13 treatment of patients with immune-mediated inflammatory diseases in observational cohort studies. BioDrugs. 2020;34(4):513\u201328. https:\/\/doi.org\/10.1007\/s40259-020-00421-2.","journal-title":"BioDrugs"},{"issue":"8","key":"1340_CR25","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1007\/s12325-021-01834-3","volume":"38","author":"JH Cheon","year":"2021","unstructured":"Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness. Adv Ther. 2021;38(8):4366\u201387. https:\/\/doi.org\/10.1007\/s12325-021-01834-3.","journal-title":"Adv Ther"},{"issue":"23","key":"1340_CR26","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1001\/jama.2021.21316","volume":"326","author":"SW Syversen","year":"2021","unstructured":"Syversen SW, J\u00f8rgensen KK, Goll GL, Brun MK, Sandanger \u00d8, Bj\u00f8rlykke KH, et al. Effect of therapeutic drug monitoring vs standard therapy during maintenance infliximab therapy on disease control in patients with immune-mediated inflammatory diseases: a randomized clinical trial. JAMA. 2021;326(23):2375\u201384. https:\/\/doi.org\/10.1001\/jama.2021.21316.","journal-title":"JAMA"},{"issue":"4","key":"1340_CR27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.dld.2018.12.002","volume":"51","author":"M Fumery","year":"2019","unstructured":"Fumery M, Tilmant M, Yzet C, Brazier F, Loreau J, Turpin J, et al. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: a systematic review and meta-analysis. Dig Liver Dis. 2019;51(4):484\u20138. https:\/\/doi.org\/10.1016\/j.dld.2018.12.002.","journal-title":"Dig Liver Dis"},{"issue":"7","key":"1340_CR28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.3899\/jrheum.140538","volume":"42","author":"D Choquette","year":"2015","unstructured":"Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and management of infusion reactions to infliximab in a prospective real-world community registry. J Rheumatol. 2015;42(7):1105\u201311. https:\/\/doi.org\/10.3899\/jrheum.140538.","journal-title":"J Rheumatol"},{"issue":"3","key":"1340_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ibd\/izz065","volume":"26","author":"N Khan","year":"2020","unstructured":"Khan N, Vallarino C, Lissoos T, Darr U, Luo M. Risk of infection and types of infection among elderly patients with inflammatory bowel disease: a retrospective database analysis. Inflamm Bowel Dis. 2020;26(3):462\u20138. https:\/\/doi.org\/10.1093\/ibd\/izz065.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"1340_CR30","doi-asserted-by":"publisher","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","volume":"115","author":"S Kedia","year":"2020","unstructured":"Kedia S, Mouli VP, Kamat N, Sankar J, Ananthakrishnan A, Makharia G, et al. Risk of tuberculosis in patients with inflammatory bowel disease on infliximab or adalimumab is dependent on the local disease burden of tuberculosis: a systematic review and meta-analysis. Am J Gastroenterol. 2020;115(3):340\u20139. https:\/\/doi.org\/10.14309\/ajg.0000000000000527.","journal-title":"Am J Gastroenterol"},{"key":"1340_CR31","unstructured":"World Health Organization. Global tuberculosis report 2022 (issued 27 October 2022). https:\/\/www.who.int\/publications\/i\/item\/9789240061729. Accessed 9 Mar 2023."},{"issue":"3","key":"1340_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/BOR.0000000000000703","volume":"32","author":"BR England","year":"2020","unstructured":"England BR, Hershberger D. Management issues in rheumatoid arthritis-associated interstitial lung disease. Curr Opin Rheumatol. 2020;32(3):255\u201363. https:\/\/doi.org\/10.1097\/BOR.0000000000000703.","journal-title":"Curr Opin Rheumatol"},{"key":"1340_CR33","doi-asserted-by":"publisher","first-page":"5919304","DOI":"10.1155\/2019\/5919304","volume":"2019","author":"G Ishikawa","year":"2019","unstructured":"Ishikawa G, Dua S, Mathur A, Acquah SO, Salvatore M, Beasley MB, et al. Concomitant interstitial lung disease with psoriasis. Can Respir J. 2019;2019:5919304. https:\/\/doi.org\/10.1155\/2019\/5919304.","journal-title":"Can Respir J"},{"issue":"2","key":"1340_CR34","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","volume":"41","author":"R Perez-Alvarez","year":"2011","unstructured":"Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum. 2011;41(2):256\u201364. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.11.002.","journal-title":"Semin Arthritis Rheum"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01340-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-023-01340-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-023-01340-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T04:17:16Z","timestamp":1697689036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-023-01340-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1340"],"URL":"https:\/\/doi.org\/10.1007\/s40264-023-01340-1","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"assertion":[{"value":"26 July 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This integrated analysis and included three Japanese post-marketing surveillances were sponsored by Nippon Kayaku Co., Ltd. (Tokyo, Japan).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Tsutomu Takeuchi has received grants from AbbVie, Asahi Kasei Pharma, Ayumi Pharmaceutical, Boehringer-Ingelheim, Chugai Pharmaceutical, Daiichi Sankyo, DNA Chip Research, Eisai, Eli Lilly Japan, Mitsubishi Tanabe Pharma, Nippon Kayaku, Ono Pharmaceutical, and UCB Japan; consulting fees from AbbVie, Astellas Pharma, Chugai Pharmaceutical, Eli Lilly Japan, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, and Taisho Pharmaceutical; and speaker fees from AbbVie, Astellas Pharma, AstraZeneca, Ayumi Pharmaceutical, Bristol Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Gilead Sciences, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Pfizer, Sanofi, Taisho Pharmaceutical, and UCB Japan. Kiyohiro Nishikawa was an employee of and holds stocks in Nippon Kayaku. Fumika Yamada is an employee of Nippon Kayaku. Akimichi Morita has received research grants from AbbVie, Eisai, Eli Lilly Japan, Janssen Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sun Pharma Japan, Taiho Pharmaceutical, Torii Pharmaceutical, and Ushio; consulting fees from Amgen, Bristol Myers Squibb, Eli Lilly Japan, Janssen Pharmaceutical, Minophagen Pharmaceutical, Nippon Boehringer Ingelheim, Nippon Kayaku, and UCB Japan; and speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Eisai, Eli Lilly Japan, Janssen Pharmaceutical, Kyowa Kirin, Maruho, Minophagen Pharmaceutical, Nippon Boehringer Ingelheim, Novartis, Sun Pharma Japan, Taiho Pharmaceutical, UCB Japan, and Ushio. Mamitaro Ohtsuki has received research grants from AbbVie, Eisai, Kyowa Kirin, Maruho, Mitsubishi Tanabe Pharma, Sun Pharma Japan, Taiho Pharmaceutical, and Torii Pharmaceutical; consulting fees from Bristol Myers Squibb, Eli Lilly Japan, LEO Pharma, Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis, and UCB Japan; and speaker fees from AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly Japan, Janssen Pharmaceutical, Kyowa Kirin, LEO Pharma, Maruho, Sanofi, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB Japan. Yasuo Suzuki has received grants from AbbVie, EA Pharma, JIMRO, Kissei Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, and Nippon Kayaku; and speaker fees from AbbVie, EA Pharma, Janssen Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Takeda Pharmaceutical, and Zeria Pharmaceutical. Mamoru Watanabe has received research funding from AbbVie, EA Pharma, Kissei Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Takeda Pharmaceutical, and Zeria Pharmaceutical; consultancy fees from AbbVie, EA Pharma, Eli Lilly Japan, Gilead Sciences, Kissei Pharmaceutical, Nichi-Iko Pharmaceutical, and Nippon Boehringer Ingelheim; and lecture fees from AbbVie, EA Pharma, Eli Lilly Japan, Gilead Sciences, Janssen Pharmaceutical, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, and Zeria Pharmaceutical. Hisashi Yamanaka has received consulting fees from AbbVie, Chugai Pharmaceutical, CorEvitas, Nippon Kayaku, Pfizer, Sato Pharmaceutical, Teijin Pharma, and YL Biologics; and speaker fees from AbbVie, Asahi Kasei Pharma, Ayumi Pharmaceutical, Bristol Meyers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Fuji Yakuhin, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Teijin Pharma, and YL Biologics. Toshifumi Hibi has received research grants or scholarship contributions from AbbVie, Activaid, Alfresa Pharma, Bristol Myers Squibb, Eli Lilly Japan, Ferring Pharmaceuticals, Gilead Sciences, Janssen Pharmaceutical, JMDA, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Nippon Kayaku, Pfizer, Takeda Pharmaceutical, and Zeria Pharmaceutical; advisory\/consultancy fees from AbbVie, Celltrion, EA Pharma, Eli Lilly Japan, Gilead Sciences, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nichi-Iko Pharmaceutical, Nippon Kayaku, Takeda Pharmaceutical, and Zeria Pharmaceutical; and lecture fees from AbbVie, EA Pharma, Janssen Pharmaceutical, JIMRO, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, Pfizer, Sandoz, Takeda Pharmaceutical, and Zeria Pharmaceutical.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocols of the PMSs were submitted to and approved by the Ministry of Health, Labour and Welfare. The protocol and ethical considerations of the PMS were reviewed and approved by internal review board members (approval numbers for PMSs in patients with rheumatoid arthritis, inflammatory bowel disease, and psoriasis are 20130717, 20140807, and 20150605, respectively) and\/or independent ethics committee at each medical institutions participating in the PMS.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The PMS was conducted in accordance with the Good Post-marketing Study Practice Ordinance of the Ministry of Health, Labour and Welfare, and informed consent from individual patients was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during the current study are available from Nippon Kayaku on reasonable request ().","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) authorship criteria for this article, and take responsibility for the integrity of the work. TT, KN, FY, AM, MO, and TH contributed to the study conceptualization and methodology. FY, AM, MO, YS, MW, HY, and TH collected data, which were analyzed and validated by KN and FY. The manuscript was drafted by KN, and critically reviewed by TT, FY, MW, HY, and TH. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}